  We discuss a cancer hallmark network framework for modelling
genome-sequencing data to predict cancer clonal evolution and associated
clinical phenotypes. Strategies of using this framework in conjunction with
genome sequencing data in an attempt to predict personalized drug targets, drug
resistance, and metastasis for a cancer patient, as well as cancer risks for a
healthy individual are discussed. Accurate prediction of cancer clonal
evolution and clinical phenotypes will have substantial impact on timely
diagnosis, personalized management and prevention of cancer.
